Forte Biosciences (FBRX) Accounts Payables (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Accounts Payables data on file, last reported at $13.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 160.48% year-over-year to $13.1 million in Q1 2026; TTM through Mar 2026 was $13.1 million, a 160.48% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 104.73% from the prior year.
• Accounts Payables for Q1 2026 stood at $13.1 million, up from $10.0 million in the prior quarter.
• Over the last five years, Accounts Payables for FBRX reached as high as $13.1 million in Q1 2026 and fell as low as $576000.0 in Q1 2022.
• Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $4.9 million in 2024.
• Across the five-year window, Accounts Payables plunged 48.88% in 2022 and surged 349.54% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $1.2 million in 2022, then advanced by 23.5% to $1.4 million in 2023, then jumped by 242.63% to $4.9 million in 2024, then jumped by 104.73% to $10.0 million in 2025, then soared by 30.98% to $13.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $13.1 million in Q1 2026, $10.0 million in Q4 2025, and $5.5 million in Q3 2025.